Nachrichten zur Hims & Hers Health Aktie

Hims & Hers Strengthens Integrated Personalized Digital Care Platform

HIMS is scaling its personalized, at-home digital care model with new testosterone, menopause and Labs launches as subscribers near 2.5…

Hims & Hers Pulls Wegovy Pill Dupe After FDA Threats — Novo Nordisk Files Patent Lawsuit Anyway

Hims & Hers introduced a $49 per month compounded semaglutide pill in early February— then pulled it from the market…

Legal pressures mount for Hims & Hers over GLP-1 sales

Presented by the Coalition to Strengthen America’s Healthcare{beacon} Health Care Health Care The Big Story Legal pressures mount for Hims &…

HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell?

Hims & Hers expands into new specialties and proactive testing while revenue and subscribers grow. However, regulatory, legal and margin…

Novo Nordisk-Aktie im Aufwind: Patentklage setzt Hims & Hers weiter unter Druck

• Novo Nordisk reicht Klage wegen Verletzung des US-Patents 8.129.343 ein• Hims & Hers stoppt die Pläne nach regulatorischem Druck…

FDA Blocks Hims & Hers $49 Compounded Wegovy Pill: What to Know

Hims & Hers has withdrawn its $49 compounded semaglutide pill after pressure from top U.S. health officials at the FDA…

Novo Nordisk sues Hims & Hers over ‘knock-off Wegovy’

Pharmaceutical giant Novo Nordisk announced Monday it is suing telemedicine platform Hims & Hers for allegedly “deceiving patients and putting…

Hims & Hers Aktie unter Beschuss! Kursziel drastisch gesenkt, aber...

Vancouver (www.aktiencheck.de) - Hims & Hers-Aktienanalyse von Canaccord Genuity:Canaccord Genuity habe nach der Klageeinreichung von Novo Nordisk das Kursziel für…

Hims & Hers says Novo Nordisk lawsuit ‘blatant attack’ on millions of Americans

Hims & Hers (HIMS) said in a post on X, formerly Twitter: “Novo Nordisk’s (NVO) lawsuit is a blatant attack…

Hims & Hers’ Woes Compound as FDA Hits Company With Warning Letter

The agency flagged several violations at a compounding pharmacy owned by Hims & Hers, including “infestation by rodents, birds insects,…

Novo Nordisk commences legal action against Hims & Hers

Danish pharma major Novo Nordisk today announced that it has now filed a previously threatened a lawsuit against telehealth…

Wegovy maker Novo Nordisk sues rival over knock-off weight-loss drugs

Novo Nordisk says Hims & Hers drugs breach its patent; Hims & Hers calls the lawsuit a "blatant attack".…

Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies

Novo Nordisks U.S. patent lawsuit against Hims & Hers , filed on Monday, marks a new front in the Danish…

Fight over GLP-1 alternatives escalates as Novo Nordisk sues Hims & Hers

Hims & Hers shares plunged Monday after Novo Nordisk filed a lawsuit and federal regulators called for an investigation.…

Hims & Hers Health: Dont Fall For The Hysteria

Hims & Hers Health trades at yearly lows amid market hysteria over compounded oral Wegovy and regulatory scrutiny. Read the…

Hims & Hers stock plunges after weight loss pill pulled amid FDA scrutiny

…

FDA warned a Hims & Hers compounder after finding bugs and failing to report a serious side effect

FDA inspectors fournd a live spider and dead cricket in a facility that was compounding weight-loss drugs for Hims &…

Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?

Hims & Hers could face difficulty in the future in selling copycat GLP-1 drugs.…

Hims & Hers Health: The Company Will Survive, But Investors Should Expect A Washout

Hims & Hers is rated Hold as regulatory/legal risks hit its GLP-1 weight-loss pivot; resilient core & strong liquidity noted.…

Hims & Hers Aktie: GLP-1-Umsätze in Gefahr!

New York (www.aktiencheck.de) - Hims & Hers-Aktienanalyse von TD Cowen:TD Cowen habe das Kursziel für die Aktie von Hims &…

Why Novo Nordisk Stock Just Popped

Novo Nordisk is suing Hims & Hers -- but Hims & Hers already surrendered.…

Why Hims & Hers Stock Just Got Destroyed

Everyones ganging up on Hims & Hers stock this week.…

Novo sues Hims & Hers despite Wegovy pill offering U-turn

Novo and Hims & Hers have continually locked horns over the legality of obesity drug offerings.…

Hims & Hers stock crashes after FDA announces plans to take decisive steps against GLP-1 compounds

Hims & Hers stock fell sharply on Monday after the FDA said it would take steps to restrict the sale…

Novo Nordisk sues Hims & Hers over copycat versions of Wegovy drugs; Hims stock plunges 27%

Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and…

Hims retreats from weight loss pill launch as Novo, FDA pressure mounts

Hims & Hers caused a firestorm last week when it revealed that it planned to launch a knockoff version of…

Eli Lilly buys Orna, Novo Nordisk sues Hims & Hers, Kyndryl plunges

There are a number of stocks moving on the morning of Monday, Feb. 9, including Eli Lilly (LLY), Novo Nordisk…

Market movers: Hims & Hers, Workday, Valaris, Monday.com...

…

Here are 10 things to watch in the stock market Monday

Shares of Eli Lilly and Novo Nordisk jumped in premarket trading after Hims & Hers said that the company will…

Lawsuit against Hims & Hers should be ‘wake-up call’ for compounders, Novo chief counsel says

Novos chief counsel says telehealth companies and compounding pharmacies that are continuing to make copycat versions of Wegovy “should be…

Assessing Hims & Hers Health (HIMS) Valuation After Compounded GLP-1 Launch And Rapid Regulatory Retreat

Hims & Hers Health (HIMS) has been at the center of attention after launching a discounted compounded semaglutide weight loss…

Wegovy maker sues Hims & Hers after company launches $49 weight-loss pill

Novos lawsuit comes less than one week after Hims & Hers announced plans to sell a compounded version of Novos…

Stocks making the biggest moves premarket: Oracle, Novo Nordisk, Hims & Hers Health, Kroger and more

These are the stocks posting the largest moves in premarket trading.…

Novo Nordisk sues Hims & Hers over patent infringement

Novo Nordisk said on Monday it has filed a lawsuit against U.S. telehealth company Hims & Hers for infringing on…

Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pill, injections

Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and…

Novo Nordisk Says It’s Suing Hims to Halt Obesity Drug Copycats

Novo Nordisk A/S said it’s suing Hims & Hers Health Inc. for making knock-offs of its obesity medicines, even as…

Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy® and Ozempic®

Novo Nordisk has filed a lawsuit against telehealth firm Hims & Hers for patent infringement and putting patients’ lives at…

Blitz-K.O. vor dem Super Bowl! Hims & Hers stoppt Billig-Wegovy nach massiven Drohungen der FDA!

Der Traum von der günstigen Abnehm-Pille ist vorerst geplatzt. Was als disruptiver Angriff auf das Milliarden-Monopol von Novo Nordisk und…

Hims & Hers, Micron, Kroger, STMicroelectronics, Nvidia, Amazon, and More Movers

Hims & Hers Health tumbles after discontinuing a compounded pill version of Novo Nordisk’s Wegovy.…

Hims & Hers retreats from compounded GLP-1 pill

Hims & Hers has relied on sales of compounded versions of GLP-1 injections to fuel its growth.…

Stocks to Watch Monday: Novo Nordisk, Hims & Hers, Apollo

?? Novo Nordisk (NVO), (DK:NOVO.B): The Danish drugmakers stock gained more than 8% after Hims & Hers (HIMS) said it…

Novo Nordisk Stock Soars After Hims & Hers Scraps Copycat Weight-Loss Pill

Novo Nordisk stock surged after Hims & Hers scrapped plans to sell a copycat version of the drugmaker’s weight-loss pill…

Novo Nordisk rises as Hims & Hers backs down on oral GLP-1

Novo Nordisks battered stock enjoyed a reprieve after Hims & Hers abandoned plans to launch a compounded version of the…

Hims & Hers: Decelerating Growth And Cowboy Management, Material Downside Risk

Hims & Hers Health faces slowing revenue/subscriber growth, premium valuation and regulatory risk from copycat obesity drugs. Learn more about…

Hims & Hers scraps low-cost weight-loss pill following backlash

Hims & Hers scraps low-cost weight-loss pill following backlash Him & Hers (NYSE:HIMS) shares are set to open 23% lower…

Hims & Hers stock poised for heavy losses after quick U-turn on plan for oral Wegovy competitor

Hims & Hers stock tumbled in early action on Monday after the U.S. company quickly reversed plans to introduce its…

Novo Nordisk pops 8% after Hims & Hers pulls copycat weight-loss pill

Novo Nordisk shares jumped 8% Monday after Hims & Hers said it will pull its copycat weight-loss pill off the market.…

Novo Nordisk shares rise as Hims abandons $49 weight-loss pill

Novo Nordisks Frankfurt-listed shares rose 4.5% on Monday after telehealth firm Hims & Hers reversed its launch of a $49…

Tensions compound in weight loss drug market

Hims & Hers announced on Thursday that it would sell a $49 compounded version of Wegovy’s weight loss pill, but…